Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Conditions
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome · Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · Refractory Myelodysplastic Syndrome · Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University, New Haven, Connecticut, United States
Contact: Principal Investigator (Maximilian Stahl)Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Principal Investigator (Michael J. Hochman)University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222Contact: Principal Investigator (Olatoyosi M. Odenike)UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
UChicago Medicine Northwest Indiana, Crown Point, Indiana, United States
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Vu H. Duong)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Evan C. Chen)Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Contact: Principal Investigator (Meagan Jacoby)Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Contact: Principal Investigator (Meagan Jacoby)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Meagan Jacoby)Siteman Cancer Center-South County, St Louis, Missouri, United States
Contact: Principal Investigator (Meagan Jacoby)Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
Contact: Principal Investigator (Meagan Jacoby)Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Contact: Principal Investigator (Tamanna Haque)Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Contact: Principal Investigator (Tamanna Haque)Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Contact: Principal Investigator (Tamanna Haque)Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Contact: Principal Investigator (Neil D. Palmisiano)Memorial Sloan Kettering Commack, Commack, New York, United States
Contact: Principal Investigator (Tamanna Haque)Memorial Sloan Kettering Westchester, Harrison, New York, United States
Contact: Principal Investigator (Tamanna Haque)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Tamanna Haque)Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Contact: Principal Investigator (Tamanna Haque)Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Contact: Principal Investigator (Madelyn Burkart)
Study leads
Evan C Chen
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO